Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
about
Fluid Biomarkers of Traumatic Brain Injury and Intended Context of UseHuman cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's diseaseNeuroproteomics as a promising tool in Parkinson's disease research.Changes in gene expression in the rat hippocampus after focal cerebral ischemia.Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's diseaseCysteine cathepsins are essential in lysosomal degradation of α-synuclein.Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairmentSphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels.Cerebrospinal fluid biomarkers in primary headache disorders.Interactions between Flow Oscillations and Biochemical Parameters in the Cerebrospinal Fluid.Biomarkers of HIV-1 associated dementia: proteomic investigation of sera.Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease.Multiplicity of cerebrospinal fluid functions: New challenges in health and diseaseChemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia.Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers.Cerebrospinal fluid in multiple sclerosis.A better understanding of molecular mechanisms underlying human disease.Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease.New insight into neurodegeneration: the role of proteomics.Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders.Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms.Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1.Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism.The challenge in translating basic research discoveries to treatment of Huntington disease.Cerebrospinal profiling of proteins, lipids, small molecules, and elements: application to the study of migraine pathophysiology.Prediction of lipid-binding sites based on support vector machine and position specific scoring matrix.Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis.Systematic Analysis of Fatty Acids in Human Cells with a Multiplexed Isobaric Tag (TMT)-Based Method.Metabolomic study of corticosterone-induced cytotoxicity in PC12 cells by ultra performance liquid chromatography-quadrupole/time-of-flight mass spectrometry.Metallomics, elementomics, and analytical techniques
P2860
Q28066813-71CC533D-2BD4-4503-880E-AB52694A0BA6Q33793583-35C7DB0A-9FB5-42F7-9C12-B35CC1783204Q33821316-43F40DFE-E158-40A6-9380-A695518BA2F2Q35555793-2FB78709-889D-4531-97DD-566D2CB73AC8Q35566575-739F928C-065A-450A-BC14-60CE83C93E84Q35910069-CF44357A-9CB5-4617-9321-A6A2EB52C8DEQ36121837-2FBD1E38-CF0B-4660-A852-01C0D1A3230EQ36424510-D123D7B2-6F71-4687-814C-1710D0B2386AQ36546364-78F2627A-4B0A-4DB5-98F3-E4A519D58623Q37048785-7BE8A03C-25CA-44BF-850B-9056CA6EE2D1Q37152990-D789C456-8EDE-4FD9-AEFB-A4583E33C2D8Q37163086-E07BA7EB-5F9E-4F23-8CB3-B1187B937384Q37163564-3602A6C1-CB61-44A3-9D37-D18273505F64Q37352921-03B7FE3F-E583-4552-A4C5-6B4281F37FDEQ37360519-753CCC7E-E7C1-4C5E-AE4E-AE94747288F8Q37461052-8EABE3C5-5328-4C54-AA5C-864313BE98C6Q37698240-994E2FD9-652E-44ED-A966-D6AA66514C28Q37817134-921881E5-20DF-45A8-A44D-EB3862C81956Q37876426-8EE4860B-5761-4389-A0AD-A52B8304E1DEQ38170010-27F8409F-DFB9-40AF-AD10-B5520BB0F299Q38629703-5B582DD8-091C-4F9B-BFED-FDE1E2A3DC69Q38805367-EFEBB58F-E459-4E45-AF11-7BF7E4068E98Q38879553-20063756-ECEF-4E6C-AAD2-F8E21E8C6876Q38926696-5DBDAFFD-5087-4331-A5ED-BCB057F398F3Q41967848-D6DBF164-4AF8-48AE-8AFE-2341CA8BB4C1Q45302260-0B80A6ED-67B3-49F8-841B-687873AE31EEQ47422328-E215640B-F2BA-4E4D-9FE7-151BA1A27AD1Q49269072-6C5BD78A-F6A7-4591-AFBE-FED443D17D9DQ52361886-5CFEE88A-4433-47A1-8416-FF303FC9FAECQ53209811-33EB23AC-D972-46E3-8BC3-22D18A43BFE8Q57961510-488A3C2F-5283-4441-B5F3-162AFDAAB4F0
P2860
Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Identification of disease mark ...... ipidomic and proteomic methods
@ast
Identification of disease mark ...... ipidomic and proteomic methods
@en
type
label
Identification of disease mark ...... ipidomic and proteomic methods
@ast
Identification of disease mark ...... ipidomic and proteomic methods
@en
prefLabel
Identification of disease mark ...... ipidomic and proteomic methods
@ast
Identification of disease mark ...... ipidomic and proteomic methods
@en
P2093
P921
P356
P1433
P1476
Identification of disease mark ...... ipidomic and proteomic methods
@en
P2093
Alfred N Fonteh
Andreas F Huhmer
James N Riggins
Michael G Harrington
Robert J Harrington
Roger G Biringer
P356
10.1155/2006/202938
P577
2006-01-01T00:00:00Z